<DOC>
	<DOCNO>NCT00736515</DOCNO>
	<brief_summary>In recent year , research pathogenesis diabetes mellitus mechanism oral antidiabetes drug , early combination therapy oral antidiabetes drug insulin get pay attention . A lot study confirm Gliclazide MRs excellent reduce blood glucose efficacy vascular protection . Based theory practice , study design demonstrate whether combination therapy Gliclazide MR basal insulin control blood glycemia effectively reduce dosage insulin hypoglycemia event compare premix insulin monotherapy .</brief_summary>
	<brief_title>Study Combination Therapy Gliclazide MR Basal Insulin Versus Insulin Monotherapy Treat Type 2 Diabetes</brief_title>
	<detailed_description>Inclusion criterion : 1 . Male female type 2 diabetes mellitus 2 . 35 year old≤age≤65 year old 3 . 19kg/m2≤BMI≤32kg/m2 4 . Uncontrolled blood glycemia ( FPG≥7.0mmol/L 7.5 % &lt; HbA1c≤10 % ) oral antidiabetes drug treatment 3 month 5 . Treated diet controlling , 1 secretagogue agent another oral antidiabetes drug , daily dosage secretagogue agent 50 % maximum 6 . Not participated clinical study within past 3 month 7 . Well know study sign inform consent form Exclusion criterion : 1 . Unable sign inform consent form 2 . Treated insulin , even transient usage within past 1 year 3 . Type 1 diabetes mellitus 4 . Abnormal condition gastrointestinal tract absorption oral drug 5 . Insufficient liver kidney function : ALT≥2.5 time upper limit normal value range serum creatinine≥the upper limit normal value range 6 . Encountered cardiovascular event angina pectoris , myocardial infarction , severe ventricular arrhythmia , cerebral hemorrhage , cerebral infarction , heart failure ect . within past half year 7 . Usage hormone medicine cortical hormone , immunosuppressive agent cytotoxic drug within past 2 month 8. psychotic 9 . Allergic history sulfonylurea drug 10 . Diabetic coma diabetic ketoacidosis 11 . In use miconazole 12 . Pregnancy breed woman Primary endpoint : Decreasing value FPG HbA1c , Dosage insulin , Control rate FPG Second Endpoints : 1 . MBG , SDBG , MAGE MODD 48th CGMS 2 . Incidence hypoglycemia severe hypoglycemia 3 . Weight change</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Gliclazide</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female type 2 diabetes mellitus 2 . 35 year old≤age≤65 year old 3 . 19kg/m2≤BMI≤32kg/m2 4 . Uncontrolled blood glycemia ( FPG≥7.0mmol/L 7.5 % &lt; HbA1c≤10 % ) oral antidiabetes drug treatment 3 month 5 . Treated diet controlling , 1 secretagogue agent another oral antidiabetes drug , daily dosage secretagogue agent 50 % maximum 6 . Not participated clinical study within past 3 month 7 . Well know study sign inform consent form Exclusion criterion : 1 . Unable sign inform consent form 2 . Treated insulin , even transient usage within past 1 year 3 . Type 1 diabetes mellitus 4 . Abnormal condition gastrointestinal tract absorption oral drug 5 . Insufficient liver kidney function : ALT≥2.5 time upper limit normal value range serum creatinine≥the upper limit normal value range 6 . Encountered cardiovascular event angina pectoris , myocardial infarction , severe ventricular arrhythmia , cerebral hemorrhage , cerebral infarction , heart failure ect . within past half year 7 . Usage hormone medicine cortical hormone , immunosuppressive agent cytotoxic drug within past 2 month 8. psychotic 9 . Allergic history sulfonylurea drug 10 . Diabetic coma diabetic ketoacidosis 11 . In use miconazole 12 . Pregnancy breed woman</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>combination therapy , monotherapy , gliclazide MR , insulin , CGMS</keyword>
</DOC>